<DOC>
	<DOCNO>NCT01342198</DOCNO>
	<brief_summary>The purpose study 1 ) evaluate extent absorption single dose pregabalin control release tablet without coadministration erythromycin 2 ) evaluate safety tolerability single dose pregabalin control release tablet without coadministration erythromycin .</brief_summary>
	<brief_title>An Investigation Effects Erythromycin Pharmacokinetics Pregabalin Controlled Release Tablet</brief_title>
	<detailed_description>Evaluate absorption , pharmacokinetics , safety/tolerability single dose pregabalin CR tablet without erythromycin</detailed_description>
	<mesh_term>Erythromycin</mesh_term>
	<mesh_term>Erythromycin Estolate</mesh_term>
	<mesh_term>Erythromycin Ethylsuccinate</mesh_term>
	<mesh_term>Erythromycin stearate</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Healthy male female Between age 18 55 year , inclusive Body Mass Index ( BMI ) 17.5 30.5 kg/m2 Illicit drug use Pregnant nursing female Females childbearing potential unwilling unable use acceptable method contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>pregabalin</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>bioavailability</keyword>
	<keyword>bioequivalence</keyword>
</DOC>